World’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
DetailsGuangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase III clinical studyfor BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The clinical study is a randomized,double-blind, para...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177) ,a commercial-stage biopharmaceutical company, today announced that dosing hasbegun in a Phase I clinical study to compare the pharmacokinetics and safety ofBAT2606, a proposed biosimilar of Nucala ® (mepolizumab), toUS-sourc...
Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, announced today the details of its poster presentation at the VaccinesSummit 2022, being held fromOctober 11-13inWashingtonD.C. Bio-Thera will present research andpreclinical resul...